Evogene Announces Acute Graft-Versus-Host Disease as Target Indication for Internal AI-Driven Drug Discovery Program

Article summary

Evogene Ltd. has identified acute graft-versus-host disease (aGVHD) as the primary target indication for its internal AI-driven small-molecule drug discovery program.